APELLIS PHARMACEUTICAL

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

07 May 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

06 May 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

30 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Announces Craig Wheeler to Join the Board of Directors

21 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

01 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

28 Feb 2025 04:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

24 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

19 Feb 2025 23:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

14 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

27 Jan 2025 13:00:00 By Nasdaq GlobeNewswire

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

13 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces Keli Walbert to Join the Board of Directors

10 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2024 13:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

27 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

12 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

05 Nov 2024 04:05:00 By Nasdaq GlobeNewswire

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26 Oct 2024 11:00:00 By Nasdaq GlobeNewswire